Currently, the drug is only approved to treat type-2 diabetes
Still in clinical trials, this triple agonist has shown remarkable results in early studies
This is a major source of -KG in cells
The Fanconi anemia group C protein (FANCC) interacts with GSTP1 and prevents the formation of inactivating disulfide bonds within GSTP1 and increases GSTP1 activity during apoptosis
However, the cons of this ingredient may outweight the pros

were included (3 clinical trials sponsored by #FFCD, 3 cohorts) 48% metastatic, 45% doublet chemo Key findings : Factors predicting severe toxicities after 3 months of chemo : female sex, cognitive impairment in men, low albumin level, doublet chemo, impaired kidney function Factors predicting mortality at 36 months : altered IADL, anemia, increased neutrophil count, metastatic stage, and single agent chemo These results will allow treatment individualization in elderly CRC patients Patients predicted to be at risk of severe toxicities could be offered more intensive monitoring This work was supervised by Pr Thomas Aparicio & Pr Florence Canoui-Poitrine, and funded by #INCa To view or add a comment, sign in AccendoWave - A Pain #Data Company Eli Lilly is calling on European countries to make urgent improvements to their #Alzheimers disease diagnostic testing practices just weeks after nabbing a new approval on the continent for its Alzheimer's therapy Kisunla